<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000089</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00087754</org_study_id>
    <secondary_id>1U01CA210170-01</secondary_id>
    <nct_id>NCT02000089</nct_id>
  </id_info>
  <brief_title>The Cancer of the Pancreas Screening-5 CAPS5)Study</brief_title>
  <acronym>CAPS5</acronym>
  <official_title>The Cancer of the Pancreas Screening-5 CAPS5)Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Johns Hopkins clinical research office quality assurance group will monitor and audit this&#xD;
      study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal&#xD;
      monitoring at their site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sub Investigator at each site will be responsible for internal monitoring at their site.&#xD;
      The site sub Investigator and study team will report any serious adverse events to Principal&#xD;
      Investigator and annually report adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Evaluation of the effect of diagnostic tests for pancreatic cancer</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking of the diagnostic test results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate pancreatic juice for early cancer markers.</measure>
    <time_frame>10 years</time_frame>
    <description>Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare pancreas juice with pancreas cyst fluid</measure>
    <time_frame>10 years</time_frame>
    <description>Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time disease progression and prevalence</measure>
    <time_frame>10 years</time_frame>
    <description>Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age &gt;55.</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Peutz-Jeghers Syndrome (PJS)</condition>
  <condition>Gene Mutation</condition>
  <condition>Germline Mutation Carrier</condition>
  <condition>Lynch Syndrome</condition>
  <arm_group>
    <arm_group_label>Familial pancreas cancer relatives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Risk Group 2 (familial pancreatic cancer relatives):&#xD;
&gt; 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and&#xD;
come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and&#xD;
have a first-degree relationship with at least one of the relatives with pancreatic cancer.&#xD;
If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 germline mutation carrier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):&#xD;
&gt; 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.&#xD;
The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), age 40 years or older, regardless of family history of pancreas cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 germline mutation carrier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):&#xD;
&gt; 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and&#xD;
The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is &gt; 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary pancreatitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peutz-Jeghers Syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At least 30 years old, and&#xD;
at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,&#xD;
known STK11 gene mutation carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and&#xD;
have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Pancreatitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,&#xD;
have no clinical or radiologic suspicion of pancreatic cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreas cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreas cyst, IPMN evaluation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human synthetic secretin</intervention_name>
    <description>I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts</description>
    <arm_group_label>Chronic Pancreatitis</arm_group_label>
    <arm_group_label>Familial pancreas cancer relatives</arm_group_label>
    <arm_group_label>Group 1 germline mutation carrier</arm_group_label>
    <arm_group_label>Group 2 germline mutation carrier</arm_group_label>
    <arm_group_label>Hereditary pancreatitis</arm_group_label>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_label>Pancreas cancer</arm_group_label>
    <arm_group_label>Pancreas cyst, IPMN evaluation</arm_group_label>
    <arm_group_label>Peutz-Jeghers Syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hereditary Pancreatitis or&#xD;
&#xD;
          -  Peutz-Jeghers Syndrome or&#xD;
&#xD;
          -  Strong family history of pancreas cancer on one side of the family tree or&#xD;
&#xD;
          -  Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, BRCA1, HNPCC, PRSS1/2, or&#xD;
             CTRC&#xD;
&#xD;
          -  Endoscopic evaluation of pancreas scheduled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical comorbidities or coagulopathy that contraindicate endoscopy&#xD;
&#xD;
          -  Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete&#xD;
             gastrectomy with Bilroth or Roux-en-Y anastomosis&#xD;
&#xD;
          -  Stricture or obstruction in the upper GI tract that does not allow passage of the&#xD;
             echoendoscope&#xD;
&#xD;
          -  Poor performance status&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Goggins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilary Cosby, RN</last_name>
    <email>hcosby1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Merenda, BSN</last_name>
      <phone>203-785-7019</phone>
      <email>scott.merenda@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Farrell, MD</last_name>
      <email>james.j.farrell@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Farrell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Cosby, RN, CGRN</last_name>
      <phone>410-502-2893</phone>
      <email>hcosby1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Goggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center, Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blair</last_name>
      <phone>617-632-4788</phone>
      <email>emily_blair@DFCI.Harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chinedu Ukaegbu</last_name>
      <email>chinedu_ukaegbu@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sapna Syngal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Koeppe, MS</last_name>
      <phone>734-998-1274</phone>
      <email>eskoeppe@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elena Stoffel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Vasquez</last_name>
      <email>lrv2111@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Fay Kastrinos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center, Case Western Medical Reserve</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Furrey, RN</last_name>
      <phone>216-844-7314</phone>
      <email>nancy.furey@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen DeMarshall, RN</last_name>
      <phone>215-349-8546</phone>
      <email>demarshm@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Bryson Katona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Dudley</last_name>
      <email>dudleyre@mail.magee.edu</email>
    </contact>
    <contact_backup>
      <last_name>Randall Brand, MD</last_name>
      <email>brandre@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randy Brand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>familial pancreas cancer</keyword>
  <keyword>(Peutz-Jeghers Syndrome) PJS</keyword>
  <keyword>Breast cancer (BRCA) 2</keyword>
  <keyword>Partner and Locator of BRCA2 (PALB2)</keyword>
  <keyword>Familial Atypical Multiple Mole- Melanoma (FAMMM)</keyword>
  <keyword>p16</keyword>
  <keyword>Breast Cancer (BRCA)1</keyword>
  <keyword>(hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC</keyword>
  <keyword>Lynch Syndrome</keyword>
  <keyword>hereditary pancreatitis</keyword>
  <keyword>Protease Serine (PRSS)</keyword>
  <keyword>Chymotrypsin C (CTRC)</keyword>
  <keyword>Ataxia Telangiectasia Mutated(ATM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Peutz-Jeghers Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

